Valuation : Celldex Therapeutics, Inc.

Market Cap 3.07B 2.65B 2.48B 2.27B 4.27B 294B 4.28B 29.45B 11.49B 148B 11.53B 11.28B 491B P/E 2026 *
-9.37x
P/E 2027 * -9.32x
Enterprise Value 2.41B 2.08B 1.95B 1.78B 3.35B 230B 3.36B 23.1B 9.01B 116B 9.05B 8.85B 385B EV / Sales 2026 *
1,212x
EV / Sales 2027 * 204x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Celldex Therapeutics, Inc.

1 day-3.31%
1 week-3.12%
Current month+2.79%
1 month+9.95%
3 months+23.41%
6 months+30.01%
Current year+44.04%
1 week 39.04
Extreme 39.04
42.12
1 month 37.05
Extreme 37.05
45.14
Current year 22.33
Extreme 22.33
45.14
1 year 21.77
Extreme 21.77
45.14
3 years 14.4
Extreme 14.4
53.18
5 years 14.4
Extreme 14.4
57.2
10 years 1.5
Extreme 1.5
75.3
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 30/07/2014
Chief Executive Officer 64 01/09/2008
Director of Finance/CFO 55 01/04/2009
Director TitleAgeSince
Director/Board Member 64 01/12/2008
Chairman 80 05/06/2025
Director/Board Member 93 01/03/2008
Date Insider Type Main position Quantity % Market Cap.
25/6/26 Free

Executive/Senior Manager

20,000 0.0255%
25/6/26 Free

Director

26,000 0.0331%
25/6/26 Free

Chief Technology Officer

57,000 0.0726%
Change 5-day change 1-year change 3-year change Capi.($)
-3.31%-3.12%+74.80%+38.23% 3.07B
-0.78%-1.42%+2.49%+22.78% 50.47B
-6.00%-0.75%+442.41%+544.39% 44.56B
-0.24%+0.74%+38.69%+18.02% 43.08B
-1.55%-2.07%+23.08%+81.47% 41.7B
-0.31%-0.83%+16.15%+51.42% 33.21B
-1.79%-3.24%+27.00%+129.56% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.60%+27.75% 14.58B
-1.66%-1.25%+78.59%+46.66% 13.92B
Average -1.71%-1.26%+79.42%+106.70% 27.76B
Weighted average by Cap. -1.72%-1.08%+95.46%+132.51%

Financials

2026 *2027 *
Net sales 1.99M 1.71M 1.61M 1.47M 2.76M 190M 2.77M 19.06M 7.44M 95.92M 7.46M 7.3M 318M 11.92M 10.27M 9.63M 8.79M 16.56M 1.14B 16.62M 114M 44.58M 575M 44.76M 43.78M 1.91B
Net income -317M -273M -256M -234M -441M -30.31B -442M -3.04B -1.19B -15.3B -1.19B -1.16B -50.74B -355M -306M -287M -262M -493M -33.94B -495M -3.4B -1.33B -17.13B -1.33B -1.3B -56.81B
Net Debt -662M -571M -535M -488M -920M -63.3B -923M -6.35B -2.48B -31.95B -2.49B -2.43B -106B -638M -549M -515M -470M -886M -60.93B -889M -6.11B -2.38B -30.76B -2.39B -2.34B -102B
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
198
Date Price Change Volume
28/08/26 US$39.12 -3.31% 424,938
27/08/26 US$40.46 -0.27% 450,009
26/08/26 US$40.57 -1.58% 540,668
25/08/26 US$41.22 +1.60% 550,919
24/08/26 US$40.57 +0.47% 416,889
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
39.12USD
Average target price
58.07USD
Spread / Average Target
+48.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLDX Stock